Nucleobase-Adduct MR1 Ligands for T Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of identified MR1-presented tumor-associated antigens and tools to probe and modulate MR1 interactions hinders the development of effective MR1-centered immune-oncological treatments, limiting the ability to stimulate and isolate MR1-specific T cells for cancer immunotherapy.
Innovation Solution
Development of nucleobase-adduct MR1 ligand compounds that stimulate MR1-specific T cells, facilitate the identification and isolation of reactive T cells, and classify metabolically altered cells, including tumor cells, by presenting these ligands to MR1 T cells, and modulating their quantity through pharmacological intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If MR1-presented tumor-associated antigens are not identified and tools to probe MR1 interactions are not developed, then the development of effective MR1-centered immune-oncological treatments is hindered, but this lack of information also limits the ability to stimulate and isolate MR1-specific T cells for cancer immunotherapy
Solution Approach 1:
The patent uses small molecule ligands as intermediaries to bridge the gap between MR1 molecules and T cell receptors. These ligands bind to MR1 with high affinity and stability, enabling the detection and isolation of MR1-specific T cells without requiring prior knowledge of the natural antigen repertoire. The ligands serve as artificial mediators that facilitate the interaction between MR1 and T cells for therapeutic purposes.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of small molecule ligands to optimize their binding affinity, stability, and immunogenicity. By systematically varying molecular parameters such as functional groups, stereochemistry, and molecular weight, the inventors developed a library of ligands with enhanced properties for stimulating MR1-specific T cells and for use as diagnostic tools.
2Adaptability or versatility
If conventional peptide-based antigen presentation strategies are used, then the approach is limited by MHC polymorphism and competition for binding, but developing MR1-specific ligands requires overcoming the lack of known antigen repertoire
Solution Approach 1:
The patent achieves universality by developing small molecule ligands that bind to the invariant MR1 molecule, which is non-polymorphic and expressed on most cell types. Unlike peptide antigens that require specific MHC alleles for presentation, these synthetic ligands can stimulate MR1-specific T cells in all patients regardless of their genetic background, making the therapy universally applicable across diverse patient populations.
Solution Approach 2:
The patent uses small molecule ligands that can be synthesized de novo and do not require complex purification processes. These ligands can be produced cost-effectively and in large quantities, enabling their use as disposable diagnostic tools and therapeutic adjuvants. The small molecules serve as single-use reagents for T cell stimulation and identification without requiring long-term storage or complex handling.
Data Source
AI summary
The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell.The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.